Fund Details
| Ticker | THNR |
| Inception | 5/21/2024 |
| Primary Exchange | NYSE Arca |
| CUSIP | 032108532 |
| Net Assets | N/A |
| Shares Outstanding | |
| # of Holdings (view all holdings) | N/A |
| Expense Ratio: | N/A |
Fund Characteristics
| Weighted Avg. Market Cap | N/A |
| Price-to-earnings | N/A |
| Price-to-book | N/A |
| Standard deviation | N/A |
Standard deviation measures how dispersed returns are around the average. A higher standard deviation indicates that returns are spread out over a larger range of values and thus, more volatile.
Index Details
| Index Name | VettaFi Weight Loss Drug & Treatment Index |
| Index Ticker | THINR |
| Index Provider | VettaFi |
| Weighting Methodology | Float-Adjusted Market Cap |
| Rebalance Frequency | Quarterly |
| Index Website | VettaFi.com |
| Index Methodology | |
Why Invest in THNR ETF?
- Significant Growth Opportunity: The GLP-1 drug market is anticipated to grow from $6 billion to $100 billion by 2030.1
- Increasing Demand: Pharmaceutical companies are accelerating production to meet demand as over 42% of U.S. adults and 1 billion people worldwide are obese.2
- Diversified Access: A global equity portfolio of companies pioneering GLP-1 therapies and the broader supply chain to capitalize on demand.
Objective and Strategy
THNR provides access to global companies involved in the pharmaceutical manufacturing of GLP-1 agonist or enablers of such businesses. THNR seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index.
Beyond the Scale:
Recent studies have shown that GLP-1 drugs (glucagon-like peptide-1 agonists) have led to a 10-20% reduction in body-weight and lowered the risk of heart attack, stroke and cardiovascular death by approximately 20%.3
NAV and Market Price
| Previous Day's NAV | Previous Day's Market Price | |||
|---|---|---|---|---|
| Net Asset Value | N/A | Closing Price | N/A | |
| Daily Change | N/A | Daily Change | N/A | |
| % Daily Change | N/A | % Daily Change | N/A | |
| 30-Day Median Bid/Ask Spread | N/A | Premium/Discount % | N/A | |
| Premium Discount History | ||||
Daily Price/NAV Performance
Fund Holdings
| TOP 10 HOLDINGS | |||
|---|---|---|---|
Fund holdings are subject to change at any time and should not be considered recommendations to buy or sell any security.
THNR Selection Methodology
Eligible Universe
To be eligible companies must have a market cap of $500M+ & classify as:
- Drug Manufacturers – companies with available GLP-1 agonist drugs or are in clinical trials.
OR - Enablers – companies engaged in outsourced development and manufacturing of GLP-1 drugs or support for production and distribution.
Weighting
70% Drug Manufacturers
30% Enablers
A float-adjusted market cap weighting is applied to companies within each segment.
Rebalancing
The Index is rebalanced quarterly in March, June, September, and December.
Index Country Allocation
Index Industry Allocation
Index Thematic Allocation
Index Market Capitalization
| LARGE CAP (> $10B): | N/A |
| MID CAP ($2B - $10B): | N/A |
| SMALL CAP ($300M - < $2B): | N/A |
Fund holdings are subject to change at any time and should not be considered recommendations to buy or sell any security.
Performance
| CUMULATIVE (%) | ANNUALIZED (%) | ||||||
|---|---|---|---|---|---|---|---|
| 1 Mo. | 3 Mo. | 6 Mo. | YTD | Since Inception (5/21/24) |
1 Yr. | Since Inception (5/21/24) |
|
| Month end as of TBD | |||||||
| Fund NAV | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Closing Price | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| VettaFi Weight Loss Drug & Treatment Index | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quarter end as of TBD | |||||||
| Fund NAV | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Closing Price | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| VettaFi Weight Loss Drug & Treatment Index | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. Short-term performance, in particular, is not a good indication of the fund’s future performance, and an investment should not be made based solely on returns. Brokerage commissions will reduce returns. A fund’s NAV is the sum of all its assets less any liabilities, divided by the number of shares outstanding. The closing price or market price is the most recent price at which the fund was traded.
Indexes are unmanaged and it's not possible to invest directly in an index. The VettaFi Weight Loss Drug & Treatment Index is a float-adjusted market cap weighted index comprised of global companies who are manufacturers or enablers of the GLP-1 pharmaceutical business.
Premium/Discount
The table and line graph are provided to show the frequency at which the closing price of the Fund was at a premium (above) or discount (below) to the Fund's daily net asset value ("NAV"). The table and line graph represent past performance and cannot be used to predict future results. Shareholders may pay more than NAV when buying Fund shares and receive less than an NAV when those shares are sold because shares are bought and sold at current market prices.
This is your Counts mockup
| Calendar Year | Calendar Year through | |
|---|---|---|
| Days traded at premium | N/A | N/A |
| Days traded at net asset value | N/A | N/A |
| Days traded at discount | N/A | N/A |
There is no guarantee that distributions will be made.
Investing involves risk, including the possible loss of principal. There can be no assurance that the Fund’s investment objectives will be achieved. The fund is new with limited operating history. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. The Fund invests in securities included in its Index regardless of their investment merit and may experience tracking error: the differences in timing of trades, valuation, plus fees and expenses between fund and index.
A non-diversified fund and can invest a greater portion of its assets in securities of individual issuers which could cause greater fluctuations than a diversified fund. A narrowly focused portfolio concentrated in the pharmaceutical industry or healthcare sector, may exhibit higher volatility and be vulnerable to factors affecting them due to regulation, litigation, costs and competition.
Small and/or mid-capitalization companies may be more vulnerable to adverse general market or economic developments. Securities issued by foreign companies present risks beyond those of securities of U.S. issuers.
Amplify Investments LLC serves as the investment adviser to the Fund. Penserra Capital Management LLC serves as investment sub-adviser to the Fund.
1 Goldman Sachs, Anti-Obesity Drug Market. 10/2023.
2 World Health Organization, One in Eight People Are Now Living with Obesity, 03/2024. Pew Research Center, As Obesity Rates Rise in the US and Worldwide, New Weight Loss Drugs Surge in Popularity, 03/2024.
3 Morgan Stanley, GLP-1: The Weight of Speculation, 12/2023. Medscape, Semaglutide Cuts Cardiovascular Events in Landmark Trial, 08/2023.
Twitter
LinkedIn
YouTube